Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2026-04-27 08:33:59 ET · period of report 2026-04-24 · accession 0001417952-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-27 08:33 | 2026-04-24 | NAGE | Fried Robert N | CEO, Dir | M - OptEx | $2.61 | +20.0K | 1.06M | +2% | +$52.2K |
| D | 2026-04-27 08:33 | 2026-04-24 | NAGE | Fried Robert N | CEO, Dir | M - OptEx | $0.00 | -20.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-24 | M | A | 20,000 | $2.61 | 1,058,981 | D | — | — | (F1) The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise. |
| 2 | Derivative | Stock Options (right to buy) | 2026-04-24 | M | D | 20,000 | $0.00 | 0 | D | $2.61 · 2017-11-16 to 2026-11-15 | 20,000 Common Stock |